Healthcare Industry News: HSMN NewsFeed
News Release - September 15, 2011
Court Rules in Favor of Fenwal in Nearly 6-Year U.S. Patent Dispute with HaemoneticsLAKE ZURICH, Ill.--(Healthcare Sales & Marketing Network)-- The United States District Court for the District of Massachusetts has granted Fenwal’s motions for summary judgment in two related patent lawsuits brought by Haemonetics Corporation in 2005 and 2009. In its ruling, the court held that the Fenwal Alyx® system kits do not infringe the Haemonetics patent.
A link to the Memorandum & Order, filed on September 13, 2011, can be found at www.fenwalinc.com. The decision is consistent with the June 2010 ruling in favor of Fenwal by the United States Court of Appeals for the Federal Circuit.
At issue was a centrifugal component of the Fenwal Alyx® system kit, which blood centers and hospitals use to collect red blood cells.
“We respect the intellectual property of other companies and have said from the beginning that these suits have no merit,” said Dean Gregory, Fenwal senior vice president, Commercial Operations. “Most of all, this is a victory for our customers who have supported us for years as we worked to ensure these lawsuits wouldn’t disrupt their operations.”
Fenwal, Inc. is a global medical technology company focused on improving blood collection, filtration, separation, storage and transfusion to ensure the availability, safety and effectiveness of blood components. Fenwal is unique in the depth of its experience and commitment to transfusion medicine. The company offers a broad range of products for the automated and manual collection of blood and blood components. Fenwal products and advanced collection and separation technologies are used to help treat patients on six continents. Fenwal, Inc. is based in Lake Zurich, Illinois. For more information about Fenwal, please visit www.fenwalinc.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.